Literature DB >> 12244276

The jaundiced newborn. Understanding and managing transitional hyperbilirubinemia.

D K Stevenson1, R J Wong, S R Hintz, H J Vreman.   

Abstract

Neonatal jaundice is one of the most common conditions diagnosed by the pediatrician. This normally benign transitional phenomenon is a dynamic balance between the production and elimination of bilirubin. These processes can be exacerbated by a number of pathophysiologic conditions, which cause either an increase in bilirubin production rates, such as hemolysis, or a decrease in bilirubin elimination rates, such as bilirubin conjugation defects. The most dangerous circumstance for an infant is the combination of increased bilirubin production with impaired elimination. These infants are at considerable risk for developing excessive and potentially dangerous hyperbilirubinemia and subsequent kernicterus. Therefore, the importance of early recognition of the imbalance is paramount. In this review, we will discuss the various risk factors associated with hyperbilirubinemia and describe strategies for the diagnosis and management of transitional hyperbilirubinemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12244276

Source DB:  PubMed          Journal:  Minerva Pediatr        ISSN: 0026-4946            Impact factor:   1.312


  4 in total

Review 1.  Metalloporphyrins in the management of neonatal hyperbilirubinemia.

Authors:  David K Stevenson; Ronald J Wong
Journal:  Semin Fetal Neonatal Med       Date:  2009-12-16       Impact factor: 3.926

2.  Cotoneaster: A Safe and Easy Way to Reduce Neonatal Jaundice.

Authors:  Mahmoud Rafieian-Kopaei; Abolfazl Khoshdel; Soleiman Kheiri; Rabin Shemian
Journal:  J Clin Diagn Res       Date:  2016-04-01

3.  Comparing the effect of clofibrate and phenobarbital on the newborns with hyperbilirubinemia.

Authors:  Majid Hamidi; Behnam Zamanzad; Azadeh Mesripour
Journal:  EXCLI J       Date:  2013-01-22       Impact factor: 4.068

4.  East meets West: an herbal tea finds a receptor.

Authors:  Mitchell A Lazar
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.